Company Announcement / Press release Archives

Notice of annual general meeting of Xspray Pharma AB (publ)

The shareholders of Xspray Pharma AB (publ), Reg. No. 556649-3671, are summoned to the annual general meeting on Thursday 14 May 2020 at 11.00 CEST at Advokatfirman Vinge’s office on Stureplan 8 in Stockholm. Registration starts at 10.30 CEST. Due to the current pandemic (covid-19), Xspray has taken a number of precautionary measures ahead of […]

Trading in Xspray Pharma’s shares commences today on Nasdaq Stockholm

“We are very excited about the move to the main market. This is a natural step as we approach a new phase in the company’s development and move towards commercialization of our first product. Being listed on a regulated market increases our chances to become an interesting investment for more institutional owners and international specialist […]

Bulletin from the extraordinary general meeting of Xspray Pharma AB (publ)

Adoption of incentive programme The extraordinary general meeting resolved, in accordance with the board’s proposal, to adopt a long-term incentive programme for a number of employees of Xspray. According to the incentive programme, the participants will be offered to acquire warrants which after three years will entitle the holder to subscribe for shares in the […]

The conditions for Xspray Pharma’s listing on Nasdaq Stockholm have been fulfilled

For further information, please contact: Per Andersson, CEO, Xspray Pharma AB Phone: +46 (0) 706 88 23 48 E-mail: per.andersson@xspray.com The information was sent for publication, through the agency of the contact person set out above, on March 26, 2020, at 3.15 p.m. CET. About Xspray Pharma Xspray Pharma AB (publ) is a […]

Xspray Pharma publishes prospectus in connection with its listing on Nasdaq Stockholm

The first day of trading on Nasdaq Stockholm’s main market is 27 March 2020. The last day of trading on Nasdaq First North Growth Market is 26 March 2020. Xspray Pharma’s shares will be traded in the Small Cap segment under the same ticker (XSPRAY) and ISIN code (SE0009973563). No new shares will be issued […]

Xspray Pharma approved for listing on Nasdaq Stockholm

Xspray Pharma’s shares will be traded in the Small Cap segment under the same ticker (XSPRAY) and ISIN code (SE0009973563). No new shares will be issued in connection with the listing. Shareholders of Xspray Pharma do not need to take any action in connection with the listing on Nasdaq Stockholm Main Market. Xspray Pharma has […]

Xspray receives notification of manufacturing approval and provides update on clinical studies

“We are very pleased to receive this notification from AIFA that allows us to continue our development work. It represents an important milestone since it is a formal prerequisite for our upcoming pivotal HyNap-Dasa studies and thus for the subsequent ANDA-application that is currently being prepared,” says Per Andersson, CEO of Xspray Pharma. “Naturally, Xspray […]

Xspray Pharma publishes Interim report Q4, January – December 2019

Significant events during October – December 2019 • In October, Xspray announced change of listing to Nasdaq Stockholm during the first half year 2020. • In October, IND application for HyNap-Dasa was approved by the FDA. • Xspray Pharma completed in December a directed new share issue of 1,675,162 shares of SEK 122 m […]

Notice of extraordinary general meeting of Xspray Pharma AB (publ)

Right to attend the general meeting Shareholders who wish to attend the general meeting must: · be registered in the share register maintained by Euroclear Sweden AB on Friday 20 March 2020, and must also · notify the company of their intention to attend the meeting, no later than on Friday 20 March 2020. The notification must be made […]

Three additional product patents in the US for HyNap-Dasa

“With a total of seven patents for HyNap-Dasa in our most important market, we can justifiably state that it will be extremely difficult for other players to launch a dasatinib product based on amorphous solid dispersion in the United States during the lifetime of the patent, ie until January 2033. This is undoubtably very important […]